PURPOSE: To propose a new treatment paradigm for chemical burns to the eye - in the acute and chronic phases. METHODS: Recent laboratory and clinical data on the biology and treatment of chemical burns are analyzed. RESULTS: Corneal blindness from chemical burns can now be successfully treated with a keratoprosthesis, on immediate and intermediate bases. Long term outcomes, however, are hampered by early retinal damage causing glaucoma. New data suggest that rapid diffusion of inflammatory cytokines posteriorly (TNF-α, etc) can severely damage the ganglion cells. Prompt anti-TNF-α treatment is markedly neuroprotective. Long term profound reduction of the intraocular pressure is also vital. CONCLUSION: A new regimen, in addition to standard treatment, for severe chemical burns is proposed. This involves tumor necrosis factor alpha (TNF-α) inhibition promptly after the accident (primarily for retinal neuroprotection), prophylactic maximal lowering of the intraocular pressure (starting immediately), and keratoprosthesis implantation in a later quiet state.
PURPOSE: To propose a new treatment paradigm for chemical burns to the eye - in the acute and chronic phases. METHODS: Recent laboratory and clinical data on the biology and treatment of chemical burns are analyzed. RESULTS: Corneal blindness from chemical burns can now be successfully treated with a keratoprosthesis, on immediate and intermediate bases. Long term outcomes, however, are hampered by early retinal damage causing glaucoma. New data suggest that rapid diffusion of inflammatory cytokines posteriorly (TNF-α, etc) can severely damage the ganglion cells. Prompt anti-TNF-α treatment is markedly neuroprotective. Long term profound reduction of the intraocular pressure is also vital. CONCLUSION: A new regimen, in addition to standard treatment, for severe chemical burns is proposed. This involves tumor necrosis factor alpha (TNF-α) inhibition promptly after the accident (primarily for retinal neuroprotection), prophylactic maximal lowering of the intraocular pressure (starting immediately), and keratoprosthesis implantation in a later quiet state.
Authors: Amit Todani; Irmgard Behlau; Mark A Fava; Fabiano Cade; Daniel G Cherfan; Fouad R Zakka; Frederick A Jakobiec; Yuqing Gao; Claes H Dohlman; Samir A Melki Journal: Invest Ophthalmol Vis Sci Date: 2011-12-20 Impact factor: 4.799
Authors: Simon K Law; Jennifer S Huang; Nariman Nassiri; Sasan Moghimi; Naveed Nilforushan; Azarbod Parham; Jonathan Moossai; Michelle Kim; Joseph Caprioli; Anthony J Aldave Journal: J Glaucoma Date: 2014 Oct-Nov Impact factor: 2.503
Authors: Miin Roh; Yan Zhang; Yusuke Murakami; Aristomenis Thanos; Sung Chul Lee; Demetrios G Vavvas; Larry I Benowitz; Joan W Miller Journal: PLoS One Date: 2012-07-03 Impact factor: 3.240
Authors: Alja Črnej; Masahiro Omoto; Thomas H Dohlman; Miguel Gonzalez-Andrades; Eleftherios I Paschalis; Andrea Cruzat; T H Khanh Vu; Marianne Doorenbos; Dong Feng Chen; Claes H Dohlman; Reza Dana Journal: Invest Ophthalmol Vis Sci Date: 2016-04 Impact factor: 4.799
Authors: Chengxin Zhou; Marie-Claude Robert; Vassiliki Kapoulea; Fengyang Lei; Anna M Stagner; Frederick A Jakobiec; Claes H Dohlman; Eleftherios I Paschalis Journal: Invest Ophthalmol Vis Sci Date: 2017-01-01 Impact factor: 4.799
Authors: Eleftherios I Paschalis; Fengyang Lei; Chengxin Zhou; Vassiliki Kapoulea; Reza Dana; James Chodosh; Demetrios G Vavvas; Claes H Dohlman Journal: Proc Natl Acad Sci U S A Date: 2018-11-15 Impact factor: 11.205
Authors: Takashi Ueta; Kenji Ishihara; Shoji Notomi; Jong-Jer Lee; Daniel E Maidana; Nikolaos E Efstathiou; Yusuke Murakami; Eiichi Hasegawa; Kunihiro Azuma; Tetsuya Toyono; Eleftherios I Paschalis; Makoto Aihara; Joan W Miller; Demetrios G Vavvas Journal: Proc Natl Acad Sci U S A Date: 2019-11-04 Impact factor: 11.205